


## AMENDMENTS TO THE CLAIMS

1 (previously presented). A compound having a formula:



or a pharmaceutically acceptable salt thereof, wherein

at least one amide bond of an amino acid residue represented by Xaa<sub>3</sub>, Xaa<sub>4</sub>, Xaa<sub>5</sub>, Xaa<sub>6</sub>, Xaa<sub>7</sub>, Xaa<sub>8</sub>, Xaa<sub>9</sub>, and Xaa<sub>10</sub> is N-alkylated;

Xaa<sub>1</sub> is selected from the group consisting of N-methylprolyl, and an acyl group, wherein the acyl group is selected from the group consisting of

R<sup>1</sup>-(CH<sub>2</sub>)<sub>n</sub>-C(O)-, wherein n is an integer from 0 to 8 and R<sup>1</sup> is selected from the group consisting of N-acetylamino, alkoxy, alkyl, aryl, carboxy, cycloalkenyl, cycloalkyl, heterocycle, and hydroxy; and

R<sup>2</sup>-CH<sub>2</sub>CH<sub>2</sub>-O-(CH<sub>2</sub>CH<sub>2</sub>O)<sub>p</sub>-CH<sub>2</sub>-C(O)-, wherein p is an integer from 1 to 8 and R<sup>2</sup> is selected from the group consisting of hydrogen, N-acetylamino, and alkyl;

Xaa<sub>2</sub> is an N-alkylated amino acid selected from the group consisting of N-(R<sup>3</sup>)-alanyl, N-(R<sup>3</sup>)-glycyl, N-(R<sup>3</sup>)-norvalyl, and N-(R<sup>3</sup>)-prolyl, wherein R<sup>3</sup> is C<sub>1</sub>-C<sub>5</sub>-alkyl; or Xaa<sub>2</sub> is an N-unalkylated amino acid selected from the group consisting of

β-alanyl,  
D-alanyl,  
4-aminobutyryl,  
(1R,3S)-1-aminocyclopentane-3-carbonyl,  
(1S,3R)-1-aminocyclopentane-3-carbonyl,  
(1R,4S)-1-aminocyclopent-2-ene-4-carbonyl,  
(1S,4R)-1-aminocyclopent-2-ene-4-carbonyl,  
asparaginylyl,  
3-(4-chlorophenyl)alanyl,  
3-(4-cyanophenyl)alanyl,  
glutaminylyl,  
glutamyl,  
glycyl,  
4-hydroxyprolyl,

3-(4-methylphenyl)alanyl,  
prolyl,  
seryl, and  
threonyl;

Xaa<sub>3</sub> is an N-alkylated amino acid selected from the group consisting of N-(R<sup>3</sup>)-alanyl, N-(R<sup>3</sup>)-glycyl, N-(R<sup>3</sup>)-leucyl, and N-(R<sup>3</sup>)-phenylalanyl, wherein R<sup>3</sup> is as defined above; or Xaa<sub>3</sub> is an N-unalkylated amino acid selected from the group consisting of

alanyl,  
(1S,3R)-1-aminocyclopentane-3-carbonyl,  
(1S,4R)-1-aminocyclopent-2-ene-4-carbonyl,  
asparaginyll,  
aspartyl,  
3-(3-cyanophenyl)alanyl,  
3-(4-cyanophenyl)alanyl,  
glutaminyl,  
glycyl,  
leucyl,  
lysyl(N-epsilon-acetyl),  
3-(4-methylphenyl)alanyl,  
norvalyl,  
prolyl, and  
phenylalanyl;

Xaa<sub>4</sub> is an N-alkylated amino acid selected from the group consisting of N-(R<sup>3</sup>)-alanyl, N-(R<sup>3</sup>)-glycyl, N-(R<sup>3</sup>)-homophenylalanyl, N-(R<sup>3</sup>)-isoleucyl, N-(R<sup>3</sup>)-leucyl, N-(R<sup>3</sup>)-norvalyl, N-(R<sup>3</sup>)-phenylalanyl, N-(R<sup>3</sup>)-D-phenylalanyl, N-(R<sup>3</sup>)-seryl, N-(R<sup>3</sup>)-tyrosyl, N-(R<sup>3</sup>)-valyl, and N-(R<sup>3</sup>)-D-valyl, wherein R<sup>3</sup> is as defined above; or Xaa<sub>4</sub> is an N-unalkylated amino acid selected from the group consisting of

alanyl,  
alloisoleucyl,  
allylglycyl,  
2-aminobutyryl,  
(1R,4S)-aminocyclopent-2-ene-4-carbonyl,  
asparaginyll,

aspartyl,  
3-[2-(5-bromothienyl)]alanyl,  
3-(3-chlorophenyl)alanyl,  
3-(4-chlorophenyl)alanyl,  
3-(3-cyanophenyl)alanyl,  
cyclohexylalanyl,  
3-(3,4-dimethoxyphenyl)alanyl,  
3-(3-fluorophenyl)alanyl,  
3-(4-fluorophenyl)alanyl,  
glutaminy,  
glycyl,  
histidyl,  
homophenylalanyl,  
homoseryl,  
isoleucyl,  
leucyl,  
lysyl(N-epsilon-acetyl),  
methionyl,  
methionyl(sulfone),  
3-(4-methylphenyl)alanyl,  
3-(naphth-1-yl)alanyl,  
3-(naphth-2-yl)alanyl,  
norornithyl,  
norvalyl,  
phenylalanyl,  
phenylglycyl,  
prolyl,  
3-(3-pyridyl)alanyl,  
3-(4-thiazolyl)alanyl,  
3-(2-thienyl)alanyl,  
seryl,  
seryl(O-benzyl),  
styrylalanyl,  
tryptyl,  
tyrosyl,

valyl, and  
D-valyl;

Xaa<sub>5</sub> is an N-alkylated amino acid selected from the group consisting of N-(R<sup>3</sup>)-D-homophenylalanyl, N-(R<sup>3</sup>)-D-isoleucyl, N-(R<sup>3</sup>)-D-leucyl, and N-(R<sup>3</sup>)-D-phenylalanyl, wherein R<sup>3</sup> is as defined above; or Xaa<sub>5</sub> is an N-unalkylated amino acid selected from the group consisting of

D-alanyl,  
alloisoleucyl,  
D-alloisoleucyl,  
D-2-aminobutyryl,  
D-3-(4-aminophenyl)alanyl,  
D-asparaginy,   
D-3-(3-benzothienyl)alanyl,  
D-*t*-butylglycyl,  
D-(chlorophenyl)alanyl,  
D-citrullyl,  
D-3-(3-cyanophenyl)alanyl,  
D-cyclohexylalanyl,  
cyclohexylglycyl,  
D-cysteiny, (S-acetamidomethyl),  
D-cysteiny, (S-*t*-butyl),  
D-3-(3,4-difluorophenyl)alanyl,  
D-(3,4-dimethoxyphenyl)alanyl,  
D-glutaminy,   
glycyl,  
D-homophenylalanyl,  
D-homoseryl,  
isoleucyl,  
D-isoleucyl,  
D-leucyl,  
D-lysyl(N-epsilon-nicotiny),  
D-lysyl,  
D-methionyl,  
D-3-(4-methylphenyl)alanyl,

D-3-(naphth-1-yl)alanyl,  
D-3-(naphth-2-yl)alanyl,  
D-3-(4-nitrophenyl)alanyl,  
D-norleucyl,  
D-ornithyl,  
D-penicillaminy (S-acetamidomethyl),  
D-penicillaminy (S-benzyl),  
D-penicillaminy (S-methyl),  
D-penicillaminy,  
D-3-(pentafluorophenyl)alanyl,  
D-phenylalanyl,  
D-prolyl,  
D-seryl (O-benzyl),  
D-seryl,  
D-(2-thienyl)alanyl,  
D-threonyl (O-benzyl),  
D-threonyl,  
D-3-(3-trifluoromethylphenyl)alanyl,  
D-(3,4,5-trifluorophenyl)alanyl,  
D-tryptyl,  
D-tyrosyl (O-ethyl),  
D-tyrosyl, and  
D-valyl;

Xaa<sub>6</sub> is an N-alkylated amino acid selected from the group consisting of N-(R<sup>3</sup>)-aspartyl, N-(R<sup>3</sup>)-glutamyl, N-(R<sup>3</sup>)-glycyl, N-(R<sup>3</sup>)-seryl, N-(R<sup>3</sup>)-threonyl, N-(R<sup>3</sup>)-threonyl (O-benzyl), and N-(R<sup>3</sup>)-tyrosyl, wherein R<sup>3</sup> is as defined above; or Xaa<sub>6</sub> is an N-unalkylated amino acid selected from the group consisting of

alanyl,  
allothreonyl,  
D-allothreonyl,  
allylglycyl,  
asparaginy (l),  
aspartyl,  
glutaminy (l),

glycyl,  
histidyl,  
homoseryl,  
D-homoseryl,  
3-(4-hydroxymethylphenyl)alanyl,  
isoleucyl,  
lysyl(N-epsilon-acetyl),  
methionyl,  
3-(naphth-2-yl)alanyl,  
norvalyl,  
octylglycyl,  
prolyl,  
3-(3-pyridyl)alanyl,  
seryl,  
D-seryl,  
threonyl,  
D-threonyl,  
tryptyl,  
tyrosyl, and  
tyrosyl(O-methyl);

Xaa<sub>7</sub> is an N-alkylated amino acid selected from the group consisting of N-(R<sup>3</sup>)-alanyl, N-(R<sup>3</sup>)-glycyl, N-(R<sup>3</sup>)-isoleucyl, N-(R<sup>3</sup>)-leucyl, N-(R<sup>3</sup>)-D-leucyl, N-(R<sup>3</sup>)-norleucyl, N-(R<sup>3</sup>)-norvalyl, N-(R<sup>3</sup>)-seryl, N-(R<sup>3</sup>)-threonyl, and N-(R<sup>3</sup>)-valyl, wherein R<sup>3</sup> is as defined above; or Xaa<sub>7</sub> is an N-unalkylated amino acid selected from the group consisting of

alanyl,  
allothreonyl,  
allylglycyl,  
3-(4-amidophenyl)alanyl,  
2-aminobutyryl,  
arginyl,  
asparaginyll,  
cyclohexylalanyl,  
glutaminyl,  
D-glutaminyl,

glycyl,  
homoalanyl,  
homoseryl,  
4-hydroxypropyl,  
leucyl,  
D-leucyl,  
lysyl(N-epsilon-acetyl),  
methionyl sulfone,  
methionyl sulfoxide,  
methionyl,  
norleucyl,  
norvalyl,  
D-norvalyl,  
octylglycyl,  
ornithyl(N-delta-acetyl),  
phenylalanyl,  
propargylglycyl,  
seryl,  
D-seryl,  
threonyl,  
tryptyl,  
tyrosyl, and  
valyl;

Xaa<sub>8</sub> is an N-alkylated amino acid selected from the group consisting of N-(R<sup>3</sup>)-alanyl, N-(R<sup>3</sup>)-D-alanyl, N-(R<sup>3</sup>)-isoleucyl, and N-(R<sup>3</sup>)-leucyl, wherein R<sup>3</sup> is as defined above; or

Xaa<sub>8</sub> is an N-unalkylated amino acid selected from the group consisting of

alanyl,  
alloisoleucyl,  
D-alloisoleucyl,  
allylglycyl,  
citrullyl,  
glycyl,  
isoleucyl,  
D-isoleucyl,

leucyl,  
D-leucyl,  
lysyl(N-epsilon-acetyl),  
D-lysyl(N-epsilon-acetyl),  
methionyl,  
3-(naphth-1-yl)alanyl,  
norvalyl,  
prolyl,  
D-prolyl, and  
valyl;

Xaa<sub>9</sub> is the N-alkylated amino acid N-(R<sup>3</sup>)-arginyl, wherein R<sup>3</sup> is as defined above; or  
Xaa<sub>9</sub> is an N-unalkylated amino acid selected from the group consisting of

[(4-amino-N-isopropyl)cyclohexyl]alanyl,  
3-(4-amino-N-isopropylphenyl)alanyl,  
arginyl(N<sup>G</sup>N<sup>G'</sup> diethyl),  
arginyl,  
D-arginyl,  
citrullyl,  
glutaminyl,  
3-(4-guanidinophenyl)alanyl,  
histidyl,  
homoarginyl,  
lysyl(N-epsilon-isopropyl),  
lysyl(N-epsilon-nicotinyl),  
lysyl,  
norarginyl,  
ornithyl,  
ornithyl[N-delta-(2-imidazoliny)],  
ornithyl(N-delta-isopropyl), and  
3-(3-pyridyl)alanyl;

Xaa<sub>10</sub> is an N-alkylated amino acid selected from the group consisting of N-(R<sup>3</sup>)-alanyl,  
N-(R<sup>3</sup>)-D-alanyl, N-(R<sup>3</sup>)-glycyl, N-(R<sup>3</sup>)-homoalanyl, and N-(R<sup>3</sup>)-norvalyl, wherein R<sup>3</sup> is


as defined above; or Xaa<sub>10</sub> is an N-unalkylated amino acid selected from the group consisting of

D-alanyl,  
2-aminobutyryl,  
D-2-aminobutyryl,  
2-aminoisobutyryl,  
3,4-dehydroprolyl,  
4-hydroxyprolyl,  
phenylalanyl,  
prolyl,  
D-prolyl,  
1,2,3,4-tetrahydroisoquinoline-3-carbonyl, and  
D-valyl; and

Xaa<sub>11</sub> is a hydroxy group or an amino acid amide selected from the group consisting of:

alanylamide,  
D-alanylamide,  
alanylethylamide,  
D-alanylethylamide,  
azaglycylamide,  
glycylamide,  
glycylethylamide,  
lysyl(N-epsilon-acetyl),  
D-lysyl(N-epsilon-acetyl),  
N-methyl-D-alanylamide,  
sarcosylamide,  
serylamide,  
D-serylamide,

a residue represented by the formula



a group represented by the formula  $-\text{NH}-\text{R}^6$ ; wherein

s is an integer from 0 to 8;

R<sup>4</sup> is selected from the group consisting of hydrogen, alkyl, and a 5- to 6-membered cycloalkyl ring;

$R^5$  is selected from the group consisting of hydrogen, alkoxy, alkyl, aryl, cycloalkenyl, cycloalkyl, heterocycle, and hydroxy; provided that s is not zero when  $R^5$  is hydroxy or alkoxy; and  $R^6$  is selected from hydrogen and hydroxy.

2 (previously presented). A compound according to Claim 1, wherein  $Xaa_1$  is selected from the group consisting of

acetyl,  
N-acetyl- $\beta$ -alanyl,  
butyryl,  
(4-N-acetylamino)butyryl,  
(6-N-acetylamino)caproyl,  
(8-N-acetylamino)-3,6-dioxo-octanoyl,  
caproyl,  
5-chloro-2-hydroxynicotinyl,  
5-chloro-6-hydroxynicotinyl,  
2-chloroisonicotinyl,  
2-chloro-6-methylnicotinyl,  
cyclohexylacetyl,  
furoyl,  
2-hydroxy-6-methylnicotinyl,  
6-hydroxynicotinyl,  
6-hydroxy-2-picolinyl,  
isonicotinyl,  
2-methoxyacetyl,  
2-methylnicotinyl,  
6-methylnicotinyl,  
(4-methyl)phenylacetyl,  
N-methylprolyl,  
nicotinyl,  
phenylacetyl,  
propionyl,  
shikimyl,  
succinyl, and  
tetrahydrofuroyl.

3 (previously presented). A compound according to Claim 2, wherein Xaa<sub>1</sub> is selected from the group consisting of

acetyl,  
N-methylprolyl, and  
succinyl.

4 (original). A compound according to Claim 1, wherein Xaa<sub>2</sub> is selected from the group consisting of

N-methylalanyl,  
sarcosyl,  
N-ethylglycyl,  
N-methylnorvalyl,  
N-methylprolyl,  
β-alanyl,  
4-aminobutyryl,  
asparaginyll,  
glutaminyl,  
glutamyl,  
glycyl,  
prolyl,  
seryl, and  
threonyl.

5 (original). A compound according to Claim 4, wherein Xaa<sub>2</sub> is selected from the group consisting of

sarcosyl, and  
N-methylprolyl.

6 (original). A compound according to Claim 1, wherein Xaa<sub>3</sub> is selected from the group consisting of

N-methylalanyl,  
sarcosyl,  
N-methylleucyl,  
N-methylphenylalanyl,

alanyl,  
asparaginyll,  
aspartyl,  
glutaminyll,  
glycyl,  
leucyl,  
norvalyl,  
prolyl, and  
phenylalanyl.

7 (original). A compound according to Claim 6, wherein Xaa<sub>3</sub> is selected from the group consisting of

N-methylalanyl, and  
glycyl.

8 (original). A compound according to Claim 1, wherein Xaa<sub>4</sub> is selected from the group consisting of

N-methylalanyl,  
sarcosyl,  
N-methylhomophenylalanyl,  
N-methylisoleucyl,  
N-methylleucyl,  
N-methylnorvalyl,  
N-methylphenylalanyl,  
N-methyl-D-phenylalanyl,  
N-methylseryl,  
N-methyltyrosyl,  
N-methylvalyl,  
N-methyl-D-valyl,  
3-[2-(5-bromothieryl)]alanyl,  
3-(3-chlorophenyl)alanyl,  
3-(4-chlorophenyl)alanyl,  
3-(3-cyanophenyl)alanyl,  
3-(3,4-dimethoxyphenyl)alanyl,  
3-(3-fluorophenyl)alanyl,

3-(4-fluorophenyl)alanyl,  
3-(4-methylphenyl)alanyl,  
3-(naphth-1-yl)alanyl,  
3-(naphth-2-yl)alanyl,  
3-(3-pyridyl)alanyl,  
3-(4-thiazolyl)alanyl,  
3-(2-thienyl)alanyl,  
alloisoleucyl,  
allylglycyl,  
2-aminobutyryl,  
asparaginyll,  
cyclohexylalanyl,  
glutaminyl,  
glycyl,  
histidyl,  
homophenylalanyl,  
homoseryl,  
isoleucyl,  
leucyl,  
lysyl(N-epsilon-acetyl),  
methionyl,  
methionyl(sulfone),  
norornithyl,  
norvalyl,  
phenylalanyl,  
phenylglycyl,  
prolyl,  
seryl,  
seryl(O-benzyl),  
styrylalanyl,  
tryptyl,  
tyrosyl, and  
valyl.

9 (original). A compound according to Claim 8, wherein Xaa<sub>4</sub> is selected from the group consisting of

N-methylalanyl,  
N-methylisoleucyl,  
N-methylleucyl,  
N-methylnorvalyl,  
N-methylphenylalanyl,  
N-methyl-D-phenylalanyl,  
N-methylvalyl,  
N-methyl-D-valyl,  
asparaginy,   
glutaminyl,  
isoleucyl,  
phenylalanyl, and  
valyl.

10 (original). A compound according to Claim 1, wherein Xaa<sub>5</sub> is selected from the group consisting of

N-methyl-D-homophenylalanyl,  
N-methyl-D-isoleucyl,  
N-methyl-D-leucyl,  
D-3-(4-aminophenyl)alanyl,  
D-3-(3-benzothienyl)alanyl,  
D-(chlorophenyl)alanyl,  
D-3-(3-cyanophenyl)alanyl,  
D-3-(3,4-difluorophenyl)alanyl,  
D-(3,4-dimethoxyphenyl)alanyl,  
D-3-(4-methylphenyl)alanyl,  
D-3-(naphth-1-yl)alanyl,  
D-3-(naphth-2-yl)alanyl.  
D-3-(4-nitrophenyl)alanyl,  
D-3-(pentafluorophenyl)alanyl,  
D-3-(3-trifluoromethylphenyl)alanyl,  
D-(3,4,5-trifluorophenyl)alanyl,  
D-alanyl,

alloisoleucyl,  
D-alloisoleucyl,  
D-2-aminobutyryl,  
D-asparaginyl,  
D-citrullyl,  
D-cyclohexylalanyl,  
cyclohexylglycyl,  
D-cysteinyl(S-acetamidomethyl),  
D-cysteinyl(S-*t*-butyl),  
D-glutaminy,  
glycyl,  
D-homophenylalanyl,  
D-homoseryl,  
isoleucyl,  
D-isoleucyl,  
D-leucyl,  
D-lysyl(N-epsilon-nicotinyl),  
D-lysyl,  
D-methionyl,  
D-norleucyl,  
D-ornithyl,  
D-penicillaminy(S-acetamidomethyl),  
D-penicillaminy(S-benzyl),  
D-penicillaminy(S-methyl),  
D-penicillaminy,  
D-phenylalanyl,  
D-prolyl,  
D-seryl(O-benzyl),  
D-seryl,  
D-*t*-butylglycyl,  
D-(2-thienyl)alanyl,  
D-threonyl(O-benzyl),  
D-threonyl,  
D-tryptyl,  
D-tyrosyl(O-ethyl),

D-tyrosyl, and  
D-valyl.

11 (original). A compound according to Claim 10, wherein Xaa<sub>5</sub> is selected from the group consisting of

N-methyl-D-leucyl,  
D-alloisoleucyl,  
D-isoleucyl,  
D-leucyl,  
D-homophenylalanyl, and  
D-penacillaminy(S-methyl).

12 (original). A compound according to Claim 1, wherein Xaa<sub>6</sub> is selected from the group consisting of

N-methylaspartyl,  
N-methylglutamyl,  
sarcosyl,  
N-methylseryl,  
N-methyltyrosyl,  
N-methylthreonyl,  
N-methylthreonyl(O-benzyl),  
alanyl,  
3-(4-hydroxymethylphenyl)alanyl,  
3-(naphth-2-yl)alanyl,  
3-(3-pyridyl)alanyl,  
allothreonyl,  
D-allothreonyl,  
allylglycyl,  
glutaminyl,  
glycyl,  
histidyl,  
homoseryl,  
D-homoseryl,  
isoleucyl,  
methionyl,

norvalyl,  
octylglycyl,  
prolyl,  
seryl,  
D-seryl,  
threonyl,  
D-threonyl,  
tryptyl, and  
tyrosyl.

13 (original). A compound according to Claim 12, wherein Xaa<sub>6</sub> is selected from the group consisting of

N-methylaspartyl,  
N-methylglutamyl,  
sarcosyl,  
N-methylseryl,  
N-methyltyrosyl,  
N-methylthreonyl,  
N-methylthreonyl(O-benzyl),  
allothreonyl,  
seryl,  
threonyl, and  
tyrosyl.

14 (original). A compound according to Claim 1, wherein Xaa<sub>7</sub> is selected from the group consisting of

N-methylalanyl,  
sarcosyl,  
N-methylisoleucyl,  
N-methylleucyl,  
N-methyl-D-leucyl,  
N-methylnorleucyl,  
N-methylnorvalyl,  
N-methylseryl,  
N-methylthreonyl,

N-methylvalyl,  
alanyl,  
allylglycyl,  
3-(4-amidophenyl)alanyl,  
2-aminobutyryl,  
arginyl,  
asparaginyll,  
cyclohexylalanyl,  
glutaminyl,  
D-glutaminyl,  
glycyl,  
homoalanyl,  
homoseryl,  
leucyl,  
D-leucyl,  
lysyl(N-epsilon-acetyl),  
methionyl,  
methionyl sulfone,  
methionyl sulfoxide,  
norleucyl,  
norvalyl,  
D-norvalyl,  
octylglycyl,  
ornithyl(N-delta-acetyl),  
phenylalanyl,  
propargylglycyl,  
seryl,  
D-seryl,  
tyrosyl, and  
valyl.

15 (original). A compound according to Claim 14, wherein Xaa<sub>7</sub> is selected from the group consisting of

N-methylalanyl,  
sarcosyl,

N-methylisoleucyl,  
N-methyllleucyl,  
N-methyl-D-leucyl,  
N-methylnorleucyl,  
N-methylnorvalyl,  
N-methylseryl,  
N-methylthreonyl,  
N-methylvalyl,  
norleucyl,  
norvalyl, and  
seryl.

16 (original). A compound according to Claim 1, wherein Xaa<sub>8</sub> is selected from the group consisting of

N-methylalanyl,  
N-methyl-D-alanyl,  
N-methylisoleucyl,  
N-methyllleucyl,  
3-(naphth-1-yl)alanyl,  
alanyl,  
allylglycyl,  
glycyl,  
isoleucyl,  
D-isoleucyl,  
leucyl,  
D-lysyl(N-epsilon-acetyl),  
methionyl,  
norvalyl,  
prolyl, and  
valyl.

17 (original). A compound according to Claim 16, wherein Xaa<sub>8</sub> is selected from the group consisting of

N-methylalanyl,  
N-methyl-D-alanyl,

N-methylisoleucyl,  
N-methylleucyl,  
isoleucyl,  
D-isoleucyl, and  
D-lysyl(N-epsilon-acetyl).

18 (original). The compound according to Claim 1, wherein Xaa<sub>9</sub> is selected from the group consisting of

N-methylarginyl,  
[(4-amino-N-isopropyl)cyclohexyl]alanyl,  
3-(4-amino-N-isopropylphenyl)alanyl,  
3-(4-guanidinophenyl)alanyl,  
arginyl,  
arginyl(N<sup>G</sup>N<sup>G'</sup> diethyl),  
citrullyl,  
2-[4-piperidinyl(N-amidino)]glycyl,  
glutaminyl,  
histidyl,  
homoarginyl,  
lysyl,  
lysyl(N-epsilon-isopropyl),  
lysyl(N-epsilon-nicotinyl),  
norarginyl,  
ornithyl,  
ornithyl[N-delta-(2-imidazoliny)], and  
ornithyl(N-delta-isopropyl).

19 (original). A compound according to Claim 18, wherein Xaa<sub>9</sub> is selected from the group consisting of

arginyl, and  
N-methylarginyl.

20 (original). A compound according to Claim 1, wherein Xaa<sub>10</sub> is selected from the group consisting of

N-methylalanyl,

sarcosyl,  
N-methylhomosalanyl,  
N-methylnorvalyl,  
D-alanyl,  
2-aminobutyryl,  
2-aminoisobutyryl,  
3,4-dehydroprolyl,  
4-hydroxyprolyl,  
phenylalanyl,  
prolyl,  
D-prolyl, and  
1,2,3,4-tetrahydroisoquinoline-3-carbonyl.

21 (original). A compound according to Claim 20, wherein Xaa<sub>10</sub> is selected from the group consisting of

N-methylalanyl,  
sarcosyl,  
N-methylnorvalyl, and  
prolyl.

22 (original). A compound according to Claim 1, wherein Xaa<sub>11</sub> is selected from the group consisting of

alanylamide,  
D-alanylamide,  
alanylethylamide,  
D-alanylethylamide,  
azaglycylamide,  
NH-cyclobutyl,  
NH-cycloheptyl,  
NH-1-(cyclohexyl)ethyl,  
NH-2-(cyclohexyl)ethyl,  
NH-2-(ethoxy)ethyl,  
NH-ethyl,  
NH-glycyl,  
glycylethylamide,

NH-hexyl,  
NH-2-(hydroxy)ethyl,  
NH-isoamyl,  
NH-isobutyl,  
NH-2-(isopropoxy)ethyl,  
NH-isopropyl,  
lysyl(N-epsilon-acetyl),  
D-lysyl(N-epsilon-acetyl),  
NH-2-(methoxy)ethyl,  
NH-3-(methoxy)propyl,  
N-methyl-D-alanylamide,  
NH-propyl,  
NH-2-(1-pyrrolidine)ethyl,  
sarcosylamide,  
serylamine, and  
D-serylamine.

23 (original). A compound according to Claim 22, wherein Xaa<sub>11</sub> is selected from the group consisting of

NH-ethyl, and  
D-alanylamide.

24 (previously presented). A compound according to Claim 1, wherein

Xaa<sub>1</sub> is selected from the group consisting of  
acetyl,  
N-methylprolyl, and  
succinyl;

Xaa<sub>2</sub> is selected from the group consisting of  
sarcosyl, and  
N-methylprolyl;

Xaa<sub>3</sub> is selected from the group consisting of  
N-methylalanyl, and

glycyl;

Xaa<sub>4</sub> is selected from the group consisting of

N-methylalanyl,  
N-methylisoleucyl,  
N-methylleucyl,  
N-methylnorvalyl,  
N-methylphenylalanyl,  
N-methyl-D-phenylalanyl,  
N-methylvalyl,  
N-methyl-D-valyl,  
asparaginy,   
glutaminyl,  
isoleucyl,  
phenylalanyl, and  
valyl;

Xaa<sub>5</sub> is selected from the group consisting of

N-methyl-D-leucyl,  
D-alloisoleucyl,  
D-isoleucyl,  
D-leucyl,  
D-homophenylalanyl, and  
D-penacillaminy, (S-methyl);

Xaa<sub>6</sub> is selected from the group consisting of

N-methylaspartyl,  
N-methylglutamyl,  
sarcosyl,  
N-methylseryl,  
N-methyltyrosyl,  
N-methylthreonyl,  
N-methylthreonyl(O-benzyl),  
allothreonyl,  
seryl,

threonyl, and  
tyrosyl;

Xaa<sub>7</sub> is selected from the group consisting of

N-methylalanyl,  
sarcosyl,  
N-methylisoleucyl,  
N-methylleucyl,  
N-methyl-D-leucyl,  
N-methylnorleucyl,  
N-methylnorvalyl,  
N-methylseryl,  
N-methylthreonyl,  
N-methylvalyl,  
norleucyl,  
norvalyl, and  
seryl;

Xaa<sub>8</sub> is selected from the group consisting of

N-methylalanyl,  
N-methyl-D-alanyl,  
N-methylisoleucyl,  
N-methylleucyl,  
isoleucyl,  
D-isoleucyl, and  
D-lysyl(N-epsilon-acetyl);

Xaa<sub>9</sub> is selected from the group consisting of

arginyl, and  
N-methylarginyl;

Xaa<sub>10</sub> is selected from the group consisting of

N-methylalanyl,  
sarcosyl,  
N-methylnorvalyl, and

prolyl; and

Xaa<sub>11</sub> is selected from the group consisting of  
NH-ethyl, and  
D-alanylamide.

25 (original). A compound according to Claim 24 wherein Xaa<sub>1</sub> is selected from the group consisting of

acetyl, and  
succinyl.

26 (original). A compound according to Claim 24 wherein Xaa<sub>2</sub> is sarcosyl.

27 (original). A compound according to Claim 24 wherein Xaa<sub>4</sub> is selected from the group consisting of

N-methyleucyl,  
N-methylnorvalyl,  
N-methylphenylalanyl,  
N-methyl-D-phenylalanyl, and  
valyl.

28 (original). A compound according to Claim 24 wherein Xaa<sub>5</sub> is selected from the group consisting of

N-methyl-D-leucyl,  
D-alloisoleucyl,  
D-isoleucyl, and  
D-leucyl;

29 (original). A compound according to Claim 24 wherein Xaa<sub>6</sub> is selected from the group consisting of

sarcosyl,  
N-methylseryl,  
N-methyltyrosyl,  
allothreonyl,  
seryl, and

threonyl.

30 (original). A compound according to Claim 24 wherein Xaa<sub>7</sub> is selected from the group consisting of

N-methylalanyl,  
N-methylnorvalyl,  
N-methylvalyl, and  
norvalyl.

31 (original). A compound according to Claim 24 wherein Xaa<sub>8</sub> is selected from the group consisting of

N-methyllaucyl, and  
isoleucyl.

32 (original). A compound according to Claim 24 wherein Xaa<sub>9</sub> is arginyl.

33 (original). A compound according to Claim 24 wherein Xaa<sub>10</sub> is selected from the group consisting of

N-methylalanyl, and  
prolyl.

34 (currently amended). A ~~pharmaceutical~~ composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

35 (canceled). A method of treating a patient in need of anti-angiogenesis therapy comprising administering to the patient in need a therapeutically effective amount of a compound of Claim 1.

36 (canceled). A composition for the treatment of a disease selected from cancer, arthritis, psoriasis, angiogenesis of the eye associated with infection or surgical intervention, macular degeneration and diabetic retinopathy comprising a compound of Claim 1 in combination with a pharmaceutically acceptable carrier.

37 (canceled). A method of isolating a receptor from an endothelial cell comprising binding compound of Claim 1 to the receptor to form a peptide receptor complex; isolating the peptide receptor complex; and purifying the receptor.

38 (previously presented). A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of

N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-SarNH-ethyl,  
N-Succinyl-Sar-Gly-Val-D-Leu-Thr-NMeNva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-NMeArg-ProNH-ethyl,  
N-Ac-Sar-Gly-NMeVal-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-NMeIle-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-NMeAla-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,  
N-MePro-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-Ile-NMeThr(Bzl)-Nva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-Ile-Thr-Sar-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-Ile-Thr-NMeLeu-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-alloIle-Thr-NMeVal-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-Ile-Thr-NMeVal-Ile-Arg-Pro-D-AlaNH<sub>2</sub>,  
N-Ac-Sar-Gly-Val-D-Ile-NMeThr-Nva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-alloIle-Thr-NMeSer-Ile-Arg-Pro-D-AlaNH<sub>2</sub>,  
N-Ac-Sar-Gly-Phe-D-Ile-Thr-NMeVal-Ile-Arg-Pro-D-AlaNH<sub>2</sub>,  
N-Ac-Sar-Gly-Val-D-alloIle-Tyr-NMeNva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-alloIle-Tyr-NMeVal-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Gln-D-Ile-Thr-NMeNva-Ile-Arg-Pro-D-AlaNH<sub>2</sub>,  
N-Ac-Sar-Gly-Val-D-alloIle-NMeThr-Nva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-Ile-Thr-NMeSer-Ile-Arg-Pro-D-AlaNH<sub>2</sub>,  
N-Ac-Sar-Gly-NMeVal-D-Ile-Thr-Nva-Ile-Arg-Pro-D-AlaNH<sub>2</sub>,  
N-Ac-Sar-Gly-NMeVal-D-alloIle-Thr-Nva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-HpHe-Thr-NMeNva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-HpHe-Thr-NMeVal-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-Pen(SMe)-Thr-NMeNva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-Pen(SMe)-Thr-NMeVal-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-NMeNvaNH-ethyl,  
N-Ac-Sar-Gly-Val-NMe-D-Leu-Ser-Nva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Asn-NMe-D-Leu-Ser-Nva-Ile-Arg-ProNH-ethyl,

NAc-Sar-Gly-Asn-D-Leu-NMeSer-Nva-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-Val-D-alloIle-NMeSer-Nva-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-Val-D-Ile-Thr-NMeNle-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-Val-D-Ile-Sar-Nva-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-Val-D-alloIle-Sar-Nva-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-Val-D-Ile-Thr-Nva-NMeAla-Arg-ProNH-ethyl,  
NAc-Sar-Gly-Val-D-Ile-NMeAsp-Nva-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-Val-D-Ile-Thr-NMe-D-Leu-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-Val-D-Ile-NMeGlu-Nva-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-NMe-D-Val-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-NMe-D-Phe-D-Ile-Thr-Nva-Ile-Arg-Pro-D-AlaNH<sub>2</sub>,  
NAc-Sar-Gly-Val-D-Ile-Thr-Nva-NMeLeu-Arg-ProNH-ethyl,  
NAc-Sar-Gly-Asn-D-Leu-NMeSer-Nva-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-Val-D-alloIle-NMeSer-Ser-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-Val-D-Ile-Thr-Nva-NMe-D-Ala-Arg-ProNH-ethyl,  
NAc-Sar-Gly-Val-D-Ile-Thr-NMeNva-D-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-Val-D-Ile-alloThr-NMeNva-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-Gln-D-Ile-Thr-NMeNva-D-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-Gln-D-alloIle-NMeTyr-Nva-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-Gln-D-alloIle-NMeTyr-Nva-D-Ile-Arg-ProNH-ethyl, and  
NAc-Sar-Gly-Phe-D-Ile-Thr-NMeNva-Ile-Arg-Pro-D-AlaNH<sub>2</sub>.

39 (original). A compound or a pharmaceutically acceptable salt thereof, selected from the group consisting of

N-Ac-Sar-Gly-Val-D-Ile-Thr-NMeNva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-NMeIle-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-Ile-Thr-NMeAla-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-Ile-Thr-NMeVal-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-NMeAlaNH-ethyl,  
N-Succinyl-Sar-Gly-Val-D-Ile-Thr-NMeNva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-NMeAla-Val-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-NMePhe-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-NMeNva-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-Leu-Sar-Nva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-NMeLeu-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,

N-Ac-Sar-Gly-Val-D-alloIle-Thr-NMeNva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-Ile-Thr-NMeNva-Ile-Arg-Pro-D-AlaNH<sub>2</sub>,  
N-Ac-Sar-Gly-Val-D-Ile-NMeSer-Nva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-Leu-NMeSer-Nva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-Leu-Ser-NMeNva-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-alloIle-Ser-NMeSer-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-alloIle-Thr-NMeSer-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-Ile-Thr-NMeSer-Ile-Arg-ProNH-ethyl,  
N-Ac-Sar-Gly-Val-D-alloIle-NMeSer-Ser-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-Val-NMe-D-Leu-Thr-Nva-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-NMeNva-D-alloIle-Thr-Nva-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-NMePhe-D-Ile-Thr-Nva-Ile-Arg-Pro-D-AlaNH<sub>2</sub>,  
NAc-Sar-Gly-Val-D-Ile-alloThr-NMeNle-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-NMe-DPhe-D-Ile-Thr-Nva-Ile-Arg-ProNH-ethyl,  
NAc-Sar-Gly-Val-D-alloIle-Ser-NMeSer-Ile-Arg-Pro-D-AlaNH<sub>2</sub>,  
NAc-Sar-Gly-Val-D-alloIle-NMeTyr-Nva-Ile-Arg-ProNH-ethyl, and  
NAc-Sar-Gly-Val-D-Ile-Thr-NMeNva-DLys(Ac)-Arg-ProNH-ethyl.

40 (new). A composition comprising a pharmaceutically acceptable carrier and a compound according to claim 1 in an amount effective to inhibit angiogenesis.

41 (new). A composition comprising a pharmaceutically acceptable carrier and a compound according to claim 1 in an amount effective to inhibit growth of tumor cells.